{"entity":{"id":"step-pharma","kind":"company","name":"Step Pharma","aka":["Step Pharma SAS"],"tldr":"Step Pharma is a French biotech whose oral drug STP938 blocks CTPS1, an enzyme that dividing lymphocytes depend on, to treat T-cell and B-cell lymphomas.","summary":"Step Pharma develops selective inhibitors of cytidine triphosphate synthase 1 (CTPS1), an enzyme discovered through a rare human immunodeficiency to be essential for lymphocyte proliferation but dispensable for most other cells. STP938 is an oral CTPS1 inhibitor in a phase 1/2 trial in relapsed or refractory T-cell and B-cell lymphomas, and the mechanism is also being explored in autoimmune disease.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["stp938"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Saint-Genis-Pouilly","country":"FR","companyType":"biotech","investors":[],"funding":[]},"route":"/companies/step-pharma/","neighbours":{"drug":[{"id":"stp938","kind":"drug","name":"STP938","route":"/drugs/stp938/"}]}}